Company news
Atossa Therapeutics, Inc. news in 2022
Atossa Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations
December 6, 2022
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 6, 2022
Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy
October 31, 2022
Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.
October 24, 2022
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
October 23, 2022
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
August 17, 2022
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 7, 2022
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
June 1, 2022
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 8, 2022
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
April 19, 2022
Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen
March 7, 2022
Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update
February 27, 2022
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
January 26, 2022
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
January 17, 2022